Newspaper publication of audited financial statement for the quarter and year ended on 31.03.2026 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mercury Laboratories has published its audited financial results for Q4 and full year FY26 ending March 31, 2026, as per SEBI regulations. The company reported total income of Rs 7,593.67 lakhs for FY26, marginally higher than Rs 7,510.12 lakhs in FY25. Net profit after tax jumped significantly to Rs 483.40 lakhs from Rs 314.49 lakhs in the previous year, representing approximately 54% growth. Quarterly performance showed Q4 net profit of Rs 122.54 lakhs compared to Rs 111.04 lakhs in Q4 FY25. Basic and diluted EPS improved to Rs 40.28 for FY26 from Rs 26.21 in FY25. The company's single business segment is pharmaceuticals products. Results were reviewed by the Audit Committee and approved by the Board on May 29, 2026, with statutory auditors expressing an unmodified opinion.
The company delivered strong profit growth with EPS increasing from Rs 26.21 to Rs 40.28, indicating improved operational efficiency despite flat revenue growth. Shareholders can view this as a positive development with better bottom-line performance.